Compare Amylx Pharmaceuticals Inc (AMLX) vs Herbalife Nutrition Ltd (HLF) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

Herbalife (HLF) trades at $13.15, up 1.94% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains stable revenue around $5B annually with improving debt metrics, though negative shareholder equity remains a concern. Recent Q1 2026 earnings beat expectations with EPS of $0.64 versus $0.607 expected, supported by strong international growth and successful $1.45B debt refinancing completed in April 2026.

HLF presents a value opportunity with low P/E (5.77) and P/S (0.27) ratios, but faces significant leverage risks and competitive pressures. Analyst sentiment leans bullish (58% buy ratings) despite technical weakness, with the stock's direction likely dependent on Q2 2026 results announcement scheduled for August 5, 2026.